Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2009

Open Access 01-12-2009 | Research article

Three years of pulmonary rehabilitation: inhibit the decline in airflow obstruction, improves exercise endurance time, and body-mass index, in chronic obstructive pulmonary disease

Authors: David Stav, Meir Raz, Isaac Shpirer

Published in: BMC Pulmonary Medicine | Issue 1/2009

Login to get access

Abstract

Background

Pulmonary rehabilitation is known to be a beneficial treatment for COPD patients. To date, however, there is no agreement for how long a rehabilitation program should be implemented. In addition, current views are that pulmonary rehabilitation does not improve FEV1 or even slow its decline in COPD patients. The aim of the study was to examine the efficacy of a 3 year outpatient pulmonary rehabilitation (PR) program for COPD patients on pulmonary function, exercise capability, and body mass index (BMI).

Methods

A matched controlled trial was performed with outcome assessments evaluated at 6, 12, 18, 24, 30, and 36 months. Eighty patients with moderate to severe COPD (age 63 ± 7 years; FEV1 48% ± 14) were recruited. The control group received standard care only, while in addition, the case study group received PR for duration of three years. These groups were matched for age, sex, BMI, FEV1% and number of pack-years smoked.

Results

The decline in FEV1 after the three years was significantly lower in the PR group compared to control, 74 ml versus 149 ml, respectively (p < 0.001). Maximal sustained work and endurance time improved after a short period of PR and was maintained throughout the study, in contrast to the control group (p < 0.01). A decreased BMI was noted in the control group after three years, while in the PR group a mild improvement was seen (p < 0.05).

Conclusion

Three years of outpatient pulmonary rehabilitation resulted in modifying the disease progression of COPD, as well as improving physical performance in these patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Rabe KR, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi F, Jenkins C, Rodriguez-Roisin R, Weel CV, Zielinski J: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007, 176: 532-55. 10.1164/rccm.200703-456SO.CrossRefPubMed Rabe KR, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi F, Jenkins C, Rodriguez-Roisin R, Weel CV, Zielinski J: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007, 176: 532-55. 10.1164/rccm.200703-456SO.CrossRefPubMed
2.
go back to reference The Lung Health Study Research Group: Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med. 2000, 343: 1902-92. 10.1056/NEJM200012283432601.CrossRef The Lung Health Study Research Group: Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med. 2000, 343: 1902-92. 10.1056/NEJM200012283432601.CrossRef
3.
go back to reference Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK: Randomised, double blind placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000, 320: 1297-303. 10.1136/bmj.320.7245.1297.CrossRefPubMedPubMedCentral Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK: Randomised, double blind placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000, 320: 1297-303. 10.1136/bmj.320.7245.1297.CrossRefPubMedPubMedCentral
4.
go back to reference Decramer M, Rutten-van Mölken M, Dekhuijzen PN, Troosters T, van Herwaarden C, Pellegrino R, van Schayck C, Olivieri D, Del Donno M, De Backer W: Effects of N-acetyl-cysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet. 2005, 365: 1552-60. 10.1016/S0140-6736(05)66456-2.CrossRefPubMed Decramer M, Rutten-van Mölken M, Dekhuijzen PN, Troosters T, van Herwaarden C, Pellegrino R, van Schayck C, Olivieri D, Del Donno M, De Backer W: Effects of N-acetyl-cysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet. 2005, 365: 1552-60. 10.1016/S0140-6736(05)66456-2.CrossRefPubMed
6.
go back to reference Nici L, Donner C, Wouters E, Zuwallack R, Ambrosino N, Bourbeau J, Carone M, Celli B, Engelen M, Fahy B: American thoracic society/european respiratory society statement on pulmonary rehabilitation. Am J Respir Crit Care Med. 2006, 173 (12): 1390-1413. 10.1164/rccm.200508-1211ST.CrossRefPubMed Nici L, Donner C, Wouters E, Zuwallack R, Ambrosino N, Bourbeau J, Carone M, Celli B, Engelen M, Fahy B: American thoracic society/european respiratory society statement on pulmonary rehabilitation. Am J Respir Crit Care Med. 2006, 173 (12): 1390-1413. 10.1164/rccm.200508-1211ST.CrossRefPubMed
7.
go back to reference Ries L, Bauldoff GS, Carlin BW, Casaburi R, Emery CF, Mahler DA, Make B, Rochester CL, ZuWallack R, Herrerias C: Pulmonary Rehabilitation, Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines. CHEST. 2007, 131: 4S-42S. 10.1378/chest.06-2418.CrossRefPubMed Ries L, Bauldoff GS, Carlin BW, Casaburi R, Emery CF, Mahler DA, Make B, Rochester CL, ZuWallack R, Herrerias C: Pulmonary Rehabilitation, Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines. CHEST. 2007, 131: 4S-42S. 10.1378/chest.06-2418.CrossRefPubMed
8.
go back to reference Griffiths TL, Burr ML, Campbell IA, Lewis-Jenkins V, Mullins J, Shiels K, Turner-Lawlor PJ, Payne N, Newcombe RG, Ionescu AA, Thomas J, Tunbridge J: Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial. Lancet. 2000, 355: 362-68. 10.1016/S0140-6736(99)07042-7.CrossRefPubMed Griffiths TL, Burr ML, Campbell IA, Lewis-Jenkins V, Mullins J, Shiels K, Turner-Lawlor PJ, Payne N, Newcombe RG, Ionescu AA, Thomas J, Tunbridge J: Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial. Lancet. 2000, 355: 362-68. 10.1016/S0140-6736(99)07042-7.CrossRefPubMed
9.
go back to reference Troosters T, Gosselink R, Decramer M: Short- and Long-term Effects of Outpatient Rehabilitation in Patients with Chronic Obstructive Pulmonary Disease: A Randomized Trial. Am J Med. 2000, 109: 207-212. 10.1016/S0002-9343(00)00472-1.CrossRefPubMed Troosters T, Gosselink R, Decramer M: Short- and Long-term Effects of Outpatient Rehabilitation in Patients with Chronic Obstructive Pulmonary Disease: A Randomized Trial. Am J Med. 2000, 109: 207-212. 10.1016/S0002-9343(00)00472-1.CrossRefPubMed
10.
go back to reference Engstrom CP, Persson LO, Larsson S, Sullivan M: Long-term effects of a pulmonary rehabilitation programme in outpatients with chronic obstructive pulmonary disease: a randomized controlled study. Scand J Rehab Med. 1999, 31: 207-213. 10.1080/003655099444371.CrossRef Engstrom CP, Persson LO, Larsson S, Sullivan M: Long-term effects of a pulmonary rehabilitation programme in outpatients with chronic obstructive pulmonary disease: a randomized controlled study. Scand J Rehab Med. 1999, 31: 207-213. 10.1080/003655099444371.CrossRef
11.
go back to reference D'Agostino RB: Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Statist Med. 1998, 17: 2265-2281. 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B.CrossRef D'Agostino RB: Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Statist Med. 1998, 17: 2265-2281. 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B.CrossRef
12.
go back to reference American Thoracic Society: Standardization of spirometry: 1994 update. Am J Respir Crit Care Med. 1995, 152: 1107-36.CrossRef American Thoracic Society: Standardization of spirometry: 1994 update. Am J Respir Crit Care Med. 1995, 152: 1107-36.CrossRef
13.
go back to reference American Thoracic Society/American College of Chest Physicians: ATS/ACCP statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2003, 167: 211-277. 10.1164/rccm.167.2.211.CrossRef American Thoracic Society/American College of Chest Physicians: ATS/ACCP statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2003, 167: 211-277. 10.1164/rccm.167.2.211.CrossRef
14.
go back to reference Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Anto JM: Regular physical activity modifies smoking-related lung function decline and reduces risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007, 175: 458-463. 10.1164/rccm.200607-896OC.CrossRefPubMed Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Anto JM: Regular physical activity modifies smoking-related lung function decline and reduces risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007, 175: 458-463. 10.1164/rccm.200607-896OC.CrossRefPubMed
15.
go back to reference Petersen AM, Pedersen BK: The anti-inflammatory effect of exercise. J Appl Physiol. 2005, 98: 1154-1162. 10.1152/japplphysiol.00164.2004.CrossRefPubMed Petersen AM, Pedersen BK: The anti-inflammatory effect of exercise. J Appl Physiol. 2005, 98: 1154-1162. 10.1152/japplphysiol.00164.2004.CrossRefPubMed
16.
go back to reference Sircar K, Hnizdo E, Petsonk E, Attfield M: Decline in lung function and mortality: implications for medical monitoring. Occup Environ Med. 2007, 64: 461-466. 10.1136/oem.2006.031419.CrossRefPubMedPubMedCentral Sircar K, Hnizdo E, Petsonk E, Attfield M: Decline in lung function and mortality: implications for medical monitoring. Occup Environ Med. 2007, 64: 461-466. 10.1136/oem.2006.031419.CrossRefPubMedPubMedCentral
17.
go back to reference Laviolette L, Bourbeau J, Bernard S, Lacasse Y, Pepin V, Breton MJ, Baltzan M, Rouleau F, Maltais F: Assessing the impact of pulmonary rehabilitation on functional status in COPD. Thorax. 2008, 63: 115-121. 10.1136/thx.2006.076844.CrossRefPubMed Laviolette L, Bourbeau J, Bernard S, Lacasse Y, Pepin V, Breton MJ, Baltzan M, Rouleau F, Maltais F: Assessing the impact of pulmonary rehabilitation on functional status in COPD. Thorax. 2008, 63: 115-121. 10.1136/thx.2006.076844.CrossRefPubMed
Metadata
Title
Three years of pulmonary rehabilitation: inhibit the decline in airflow obstruction, improves exercise endurance time, and body-mass index, in chronic obstructive pulmonary disease
Authors
David Stav
Meir Raz
Isaac Shpirer
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2009
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/1471-2466-9-26

Other articles of this Issue 1/2009

BMC Pulmonary Medicine 1/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.